Gamma Irradiation in the Pharmaceutical Manufacturing Environment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gamma Irradiation in the Pharmaceutical Manufacturing Environment
The author reviews the benefits, challenges, and considerations to be made when selecting a gamma-irradiation sterilization method.


Pharmaceutical Technology
Volume 34, pp. s40-s43

Many sterilization methods are available for pharmaceuticals, healthcare devices, and labware, including steam, sterile-filtration, ethylene oxide, vapor-phase hydrogen peroxide, electron-beam irradiation, and gamma irradiation. Each technique needs to be evaluated before use based on various criteria. Most importantly, one must consider how the technique will affect the final product characteristics and performance.

This article reviews the considerations for using gamma irradiation in pharmaceutical manufacturing. Specifically, the author examines what gamma irradiation is, how it works, and what manufacturers need to consider when evaluating the method for terminal sterilization of a product or component. The article, while not exhaustive, is intended to provoke consideration of this effective sterilization method.

Background

Gamma irradiation is a fast, effective method for sterilization. The high-energy gamma rays (i.e., photons) from Cobalt 60 result in ionization events which can cause desirable effects (e.g., sterilization) as well as potential undesirable or unintentional effects (e.g., change in the product's molecules or byproducts). Photons have no charge or mass, allowing them to penetrate deeply into a material. The photons' penetration ability makes them ideally suited for sterilization of even relatively dense products. The photons can cause electron displacement, free radical formation, and, ultimately, bond breakage, when they penetrate a product. This mode of action can change the large biological molecules needed to support life such as DNA and enzymes, effectively rendering any living organisms present nonviable and unable to reproduce (i.e., sterile).

This depth of penetration is one of the greatest advantages of gamma irradiation as a sterilization method. A pharmaceutical or healthcare product in its final package (e.g., in its shipping carton) can, in most cases, be easily penetrated with gamma irradiation. As outlined below, all sterilization methods have positive and negative characteristics that need to be evaluated on a case-by-case basis as to the specific impact on the product and process. The author will review some of the common issues related to pharmaceutical products.

Benefits of gamma irradiation include the following:

  • Depth of photon penetration allows for sterilization of materials of various density levels
  • Process does not require addition of heat or moisture
  • Well documented for its effectiveness as a sterilization process
  • Does not produce residuals as are of concern with Ethylene Oxide sterilization
  • Simple methods are available for documenting a high sterility assurance level (SAL) such as 10-6
  • Allows for terminal sterilization.

As with any process, one must also consider the potential negative aspects of its use. Because gamma irradiation produces ionization events, it can lead to unintended or undesirable effects. Each product must be tested in its final form with irradiation before a final decision to sterilize is made. A material's tolerance to gamma irradiation must be documented and its effects known. The earlier in the development process that this is done, the more time and options will be available to adapt or modify the product or processes needed to make the product successful. Early testing also means that all applicable data (e.g., safety, efficacy, and potency) is produced for a product that also includes the effects of the sterilization process.

Pharmaceutical products cover a wide range of materials (e.g., containers, closures, excipients, and processes). The following sections examine the effect of gamma irradiation as a sterilization process on these materials individually.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here